# Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion

> **NCT05565014** · EARLY_PHASE1 · UNKNOWN · sponsor: **Sheng Hu** · enrollment: 90 (estimated)

## Conditions studied

- Malignant Pleural Effusion
- Malignant Peritoneal Effusion

## Interventions

- **DRUG:** Virus Activated Killer immune Cells
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT05565014
- **Lead sponsor:** Sheng Hu
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-24
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-06-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2022-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05565014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05565014, "Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05565014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*